Furthermore, FGFR2 immunostaining was found at the invasion front of the tumor in 2.5% (6 cases), toward the gastric lumen in 19.4% (47 cases), and at the tumor center in 79.1% (189 cases) of the cases. This evidence concerns the gene FGFR2 and neoplasm.